Leflunomid Sandoz

Leflunomide, the active ingredient in Leflunomid Sandoz, is an immunomodulatory disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for systemic use. It is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis and juvenile idiopathic arthritis, helping to reduce joint inflammation and slow disease progression in adult and pediatric patients.

GNH USA supplies Leflunomid Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams, ensuring regulatory compliance and reliable delivery worldwide through a robust quality management system.

Leflunomide is used to modify immune activity in inflammatory arthritis conditions.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: alleviates skin and joint symptoms while limiting disease progression. - Juvenile idiopathic arthritis: helps control disease activity and improve functional outcomes in children.

Adverse reactions may occur with leflunomide therapy.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Headache: transient cranial discomfort. - Hypertension: elevated blood pressure readings. - Alopecia: thinning or loss of scalp hair. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Hepatotoxicity: significant elevation of liver enzymes or liver injury. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Bone marrow suppression: neutropenia, anemia, or thrombocytopenia. - Stevens‑Johnson syndrome: severe mucocutaneous reactions. - Teratogenicity: fetal malformations when exposure occurs during pregnancy.

Before initiating leflunomide, several safety considerations are recommended. - Pregnancy: contraindicated (Category X) due to high teratogenic risk. - Liver function: obtain baseline tests and monitor periodically for hepatotoxicity. - Hematology: perform regular complete blood counts to detect cytopenias. - Infection risk: assess for active infections and avoid initiating therapy during uncontrolled infection. - Vaccination: avoid live vaccines while on treatment. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Leflunomide may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, leading to higher INR. - Methotrexate: additive hepatotoxicity risk. - CYP1A2 inhibitors (e.g., fluoroquinolones, ciprofloxacin): elevated leflunomide plasma levels.

Moderate Interactions (Monitor Closely): - Live vaccines: reduced efficacy and potential safety concerns. - TNF‑α inhibitors: heightened infection susceptibility. - Statins: possible increased risk of myopathy. - Oral contraceptives: reduced effectiveness, consider alternative contraception.